Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-25. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Cut flowers with a short vase life, of less than 5 days, include dahlias, irises, peonies, daffodils, and delphinium; flowers with a medium vase life (6 to 14 days) include marigolds, snapdragons, orchids, and roses; and flowers with a long vase life (2 to 4 weeks) include tulips, carnations, and chrysanthemums. Chemical treatments that extend vase life are a major component of floriculture research. These include:
Following the referral, the Court of Appeal began to re-examine Norris' case in May 2025. The renewed appeal was described as being of interest to lawyers acting for Lucy Letby due to her case involving similar concerns about the reliability of insulin testing and expert evidence, though the Court of Appeal would later give an oblique warning against drawing such parallels when handing down its judgement. Norris was represented during the fourteen-day hearing by Michael Mansfield KC. The court reserved judgement on 6 June 2025 and then rejected Norris' appeal on 26 June, holding that there was "no doubt" about his conviction. Norris' lawyers subsequently attempted to have an unspecified point of law certified by the Supreme Court, but the required permission was denied by the Court of Appeal in September 2025.
== Season 10 (2024) == This season is themed around mad scientists, with host John Henson as the owner of "Henson Laboratories". In each challenge, bakers are asked to create desserts to appease the evil spirits that haunt the lab.
The climate of the islands is oceanic, with moderate and fairly uniform temperatures and heavy rainfall. Fogs are almost constant. Summer weather is much cooler than Southeast Alaska (around Sitka), but the winter temperature of the islands and of the Alaska Panhandle is nearly the same. According to the Köppen climate classification system, the area southwest of 53.5°N 167.0°W / 53.5; -167.0, on Unalaska Island, has a "Subpolar Oceanic Climate" (type "Cfc", as does Reykjavík, Tórshavn, Punta Arenas, Ushuaia and the Auckland Islands), characterized by the coldest month averaging above 0 °C (32 °F), one to three months averaging above 10 °C (50 °F), and no significant precipitation differences between seasons. To the northeast of that point, the climate becomes "Subarctic With Cool Summers And Year Around Rainfall" (type "Dfc", like Petropavlovsk-Kamchatsky, Murmansk, St. Moritz, and Labrador City), where it is similar albeit colder, with the coldest month averaging below 0 °C (32 °F). During the winter, the islands become the center of a semi-permanent low-pressure area called the Aleutian Low. The mean annual temperature for Unalaska, the most populated island of the group, is about 38 °F (3 °C), being about 30 °F (−1 °C) in January and about 52 °F (11 °C) in August. The highest and lowest temperatures recorded on the islands were 78 °F (26 °C) and 5 °F (−15 °C), respectively. The average amount of annual rainfall is about 80 inches (2,000 mm); Unalaska, with about 250 rainy days per year, is said to be one of the rainiest places within the U.S.
Sources: en.wikipedia.org
counterion The ion that is the counterpart to an oppositely charged ion in a dissociated ionic species; the cation that pairs with a given anion, or vice versa. For example, Na+ is the counterion to Cl−, and vice versa, in solutions of sodium chloride (NaCl).
=== British Empire Medal (BEM) === Alwyn Enoe. For services to Entrepreneurships. The Reverend Dave King, Presiding Bishop, River Sallee Pentecostal Church/Temple of Deliverance, Grenada District. For services to Religious Affairs and Social Work
=== Conflicts of interest === In 2012, Labcorp was criticized for its practice of paying the salaries of genetic counselors in hospitals and doctors' offices, which is perceived to be a possible conflict of interest.
Sources: en.wikipedia.org
Duterte's father, Vicente, died in 1968 while his mother, Soledad, died on February 4, 2012, at the age of 95. In 1973, Duterte married Elizabeth Zimmerman, a flight attendant of German American descent who traces her roots in Tuburan, Cebu. They have three children (from eldest to youngest): Paolo ("Pulong"), Sara ("Inday Sara") and Sebastian ("Baste"). In the 1990s, his son Paolo left the family for more than five years after having a son (Omar Vincent) with Lovelie Sangkola in 1994, which Duterte acknowledged to be "[o]ne of my sad events in my life". Sara and Paolo both entered politics in 2007 and 2008 respectively, while Baste, with no interest in politics, initially concentrated on business and surfing but eventually ran and won as vice mayor of Davao City in 2019. Sara was elected as Vice President in 2022. Duterte has been publicly open about his infidelity while married to Zimmerman and cited it as the reason for his failed marriage. According to newspaper columnist Ramon Tulfo, Duterte's various alleged partners included "a then agriculture undersecretary, a governor of a province, a local TV newscaster and a policewoman", with Duterte himself admitting in 2016 to having multiple girlfriends such as a cosmetics worker in a shopping mall and a cashier. In 1998, Zimmerman filed a petition in the Regional Trial Court of Pasig to nullify her marriage. Duterte never appeared in court and did not contest Zimmerman's petition. Two years later, the court decided in her favor, ending the 27-year marriage of Duterte and Zimmerman.
Ari Parata is a fictional character from the Australian television soap opera Home and Away, played by Rob Kipa-Williams. The actor had given up acting and was training for a new career as an insurance adviser when he was given the character brief for Ari. He was initially unsure about returning to acting, but he felt like the character was a good fit for him and he auditioned for the role. After winning the part, Kipa-Williams realised that he would have to relocate to Sydney for filming. He had doubts about the move, but later admitted that he was happy he went through with it, as Home and Away helped him regain his love of acting. Kipa-Williams signed a three-year contract and he began filming around May 2019. He made his first appearance during the serial's season finale on 27 November 2019. Ari was introduced along with his brother Tane Parata (Ethan Browne), their nephew Nikau Parata (Kawakawa Fox-Reo), and sister-in-law Gemma Parata (Bree Peters). They were the serial's first Māori and indigenous family to join the main cast of Home and Away. The actors wanted to include as much of the Māori culture in the show as possible and worked with the producers and scriptwriters to achieve a high level of authenticity. Ari is portrayed as being very protective of his family, but he dislikes confrontation and struggles to express his emotions. Kipa-Williams believed he was "a little bit lost", which he could relate to. It quickly emerges that Ari has spent time in prison and he is frequently frustrated about the limited opportunities available to him because of his record.
The use of animal gut strings by musicians can be traced back to the third dynasty of Egypt. In the recent past, strings were made out of lamb gut. With the advent of the modern era, musicians have tended to use strings made of silk, or synthetic materials such as nylon or steel. Some instrumentalists, however, still use gut strings in order to evoke the older tone quality. Although such strings were commonly referred to as "catgut" strings, cats were never used as a source for gut strings. Sheep gut was the original source for natural gut string used in racquets, such as for tennis. Today, synthetic strings are much more common, but the best gut strings are now made out of cow gut. Gut cord has also been used to produce strings for the snares that provide a snare drum's characteristic buzzing timbre. While the modern snare drum almost always uses metal wire rather than gut cord, the North African bendir frame drum still uses gut for this purpose. "Natural" sausage hulls, or casings, are made of animal gut, especially hog, beef, and lamb. The wrapping of kokoretsi, gardoubakia, and torcinello is made of lamb (or goat) gut. Haggis is traditionally boiled in, and served in, a sheep stomach. Chitterlings, a kind of food, consist of thoroughly washed pig's gut. Animal gut was used to make the cord lines in longcase clocks and for fusee movements in bracket clocks, but may be replaced by metal wire. The oldest known condoms, from 1640 AD, were made from animal intestine.
Insulin: promotes lipid synthesis, inhibiting lipid breakdown, and facilitating glucose transport and conversion into fatty acids. Glucagon: stimulates fatty acid oxidation and inhibits de novo fatty acid synthesis, reducing VLDL release and hepatic steatosis. Thyroid Hormone: promotes hepatic triglyceride synthesis, enhancing lipolysis, stimulating mitochondrial fatty acid β-oxidation, and regulating cholesterol levels through various mechanisms, including LDL receptor expression and bile acid excretion. Sex Hormone: Estrogen: decreases triglyceride synthesis and enhances HDL cholesterol levels, potentially through promoting fatty acid oxidation and inhibiting lipogenesis. Testosterone: stimulates de novo lipogenesis and fat accumulation which are then incorporated to triglycerides for energy storage. Adrenaline: stimulates lipolysis and inhibits lipogenesis via AMPK phosphorylation, influencing lipid turnover and accumulation in adipose tissue.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.